Cas9‐Cleavage Sequences in Size‐Reduced Plasmids Enhance Nonviral Genome Targeting of CARs in Primary Human T Cells

• DOI: 10.1002/smtd.202100071
• Publication Date: 2021-05-20T06:56:29Z
• Authors: Ruirui Jing; Peng Jiao; Jiangqing Chen; Xianhui Meng; Xiaoyan Wu; Yanting Duan; Kai Shang; Liling Qian; Yanjie Huang; Junwei Liu; Tao Huang; Jin Jin; Wei Chen; Xun Zeng; Weiwei Yin; Xiaofei Gao; Chun Zhou; Michel Sadelain; Jie Sun
• Keywords: Gene Editing; 0301 basic medicine; 0303 health sciences; T-Lymphocytes; Genetic Vectors; DNA; Immunotherapy, Adoptive; 3. Good health; Mice; 03 medical and health sciences; Gene Targeting; NIH 3T3 Cells; Animals; Humans; Immunotherapy; CRISPR-Cas Systems; Homologous Recombination; Plasmids

AbstractT cell genome editing holds great promise to advance a range of immunotherapies but is encumbered by the dependence on difficult‐to‐produce and expensive viral vectors. Here, small double‐stranded plasmid DNA modified to mediate high‐efficiency homologous recombination is designed. The resulting chimeric antigen receptor (CAR)‐T cells display a similar phenotype, transcriptional profile, and in vivo potency to CAR‐T cells generated using adeno‐associated viral vector. This method should simplify and accelerate the use of precision engineering to produce edited T cells for research and clinical purposes.